Loading
Life sciences · Journal article
BMC Endocrine Disorders · October 14, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The uric acid-to-HDL cholesterol ratio (UHR) has been proposed as a composite marker of metabolic dysregulation. This study aimed to evaluate the association between UHR and a study-defined dysmetabolic phenotype in adults with obesity, with particular consideration of the shared contribution of HDL-C to both UHR and the phenotype definition. This retrospective cross-sectional study included 2,453 adults with a body mass index (BMI) ≥ 30 kg/m² who presented to Kayseri City Hospital between March 2025 and March 2026. The study-defined dysmetabolic phenotype (Group 2) comprised participants with central obesity and reduced HDL-C accompanied by elevated triglycerides and/or impaired glucose metabolism/diabetes; all remaining participants were classified as Group (1) Importantly, reduced HDL-C alone was insufficient for classification as Group (2) UHR was calculated as (uric acid [mg/dL] / HDL-C [mg/dL]) × 100. Discriminatory performance was assessed by receiver operating characteristic (ROC) analysis, and adjusted associations were examined by multivariable logistic regression. Of 2,453 patients (81.5% female), 878 (35.8%) met the criteria for the study-defined dysmetabolic phenotype. UHR was significantly higher in this group [13.95 (IQR: 11.40–17.75) vs. 10.19 (IQR: 7.82–13.09), p < 0.001]. Reduced HDL-C was also present in 39.4% of Group 1, indicating that reduced HDL-C alone did not determine phenotype classification. ROC analysis demonstrated moderate discriminatory performance for UHR (AUC = 0.745; optimal cut-off ≥ 11.70; sensitivity 70.8%; specificity 66.8%), with significantly higher discrimination than uric acid alone (AUC = 0.580) and lower discrimination than HDL-C (AUC = 0.825; both DeLong p < 0.001). In the adjusted logistic regression model, UHR was associated with the study-defined dysmetabolic phenotype (OR = 1.356; 95% CI: 1.316–1.397; p < 0.001), although a significant quadratic term indicated a nonlinear association ( p < 0.001). Adding UHR to an HDL-C-containing clinical model produced only a small further improvement in discrimination (AUC 0.871 to 0.873). UHR was associated with a study-defined dysmetabolic phenotype characterized by reduced HDL-C accompanied by triglyceride and/or glycemic abnormalities in adults with obesity. However, its incremental discrimination beyond HDL-C was small. These findings support UHR as a complementary biochemical index rather than a replacement for HDL-C or direct assessment of metabolic abnormalities. Not applicable.